404 related articles for article (PubMed ID: 34439105)
21. PI3K/AKT pathway as a key link modulates the multidrug resistance of cancers.
Liu R; Chen Y; Liu G; Li C; Song Y; Cao Z; Li W; Hu J; Lu C; Liu Y
Cell Death Dis; 2020 Sep; 11(9):797. PubMed ID: 32973135
[TBL] [Abstract][Full Text] [Related]
22. Activation of mammalian target of rapamycin signaling pathway contributes to tumor cell survival in anaplastic lymphoma kinase-positive anaplastic large cell lymphoma.
Vega F; Medeiros LJ; Leventaki V; Atwell C; Cho-Vega JH; Tian L; Claret FX; Rassidakis GZ
Cancer Res; 2006 Jul; 66(13):6589-97. PubMed ID: 16818631
[TBL] [Abstract][Full Text] [Related]
23. Down-regulated microRNA-223 or elevated ZIC1 inhibits the development of pancreatic cancer via inhibiting PI3K/Akt/mTOR signaling pathway activation.
Zhu J; Lv J; Chen J; Zhang X; Ji Y
Cell Cycle; 2020 Nov; 19(21):2851-2865. PubMed ID: 33064959
[No Abstract] [Full Text] [Related]
24. PI3K/AKT/mTOR signalling pathway involvement in renal cell carcinoma pathogenesis (Review).
Miricescu D; Balan DG; Tulin A; Stiru O; Vacaroiu IA; Mihai DA; Popa CC; Papacocea RI; Enyedi M; Sorin NA; Vatachki G; Georgescu DE; Nica AE; Stefani C
Exp Ther Med; 2021 May; 21(5):540. PubMed ID: 33815613
[TBL] [Abstract][Full Text] [Related]
25. S9, a novel anticancer agent, exerts its anti-proliferative activity by interfering with both PI3K-Akt-mTOR signaling and microtubule cytoskeleton.
Zhang C; Yang N; Yang CH; Ding HS; Luo C; Zhang Y; Wu MJ; Zhang XW; Shen X; Jiang HL; Meng LH; Ding J
PLoS One; 2009; 4(3):e4881. PubMed ID: 19293927
[TBL] [Abstract][Full Text] [Related]
26. Inhibitors of the PI3K/Akt/mTOR Pathway in Prostate Cancer Chemoprevention and Intervention.
Roudsari NM; Lashgari NA; Momtaz S; Abaft S; Jamali F; Safaiepour P; Narimisa K; Jackson G; Bishayee A; Rezaei N; Abdolghaffari AH; Bishayee A
Pharmaceutics; 2021 Aug; 13(8):. PubMed ID: 34452154
[TBL] [Abstract][Full Text] [Related]
27. Specific gene expression signatures induced by the multiple oncogenic alterations that occur within the PTEN/PI3K/AKT pathway in lung cancer.
De Marco C; Laudanna C; Rinaldo N; Oliveira DM; Ravo M; Weisz A; Ceccarelli M; Caira E; Rizzuto A; Zoppoli P; Malanga D; Viglietto G
PLoS One; 2017; 12(6):e0178865. PubMed ID: 28662101
[TBL] [Abstract][Full Text] [Related]
28. Long noncoding RNA H19 promotes chemotherapy resistance in choriocarcinoma cells.
Yu S; Wu C; Tan Q; Liu H
J Cell Biochem; 2019 Sep; 120(9):15131-15144. PubMed ID: 31020694
[TBL] [Abstract][Full Text] [Related]
29. ARHGAP9 inhibits colorectal cancer cell proliferation, invasion and EMT via targeting PI3K/AKT/mTOR signaling pathway.
Sun J; Zhao X; Jiang H; Yang T; Li D; Yang X; Jia A; Ma Y; Qian Z
Tissue Cell; 2022 Aug; 77():101817. PubMed ID: 35679685
[TBL] [Abstract][Full Text] [Related]
30. Molecular targets for cancer therapy in the PI3K/AKT/mTOR pathway.
Polivka J; Janku F
Pharmacol Ther; 2014 May; 142(2):164-75. PubMed ID: 24333502
[TBL] [Abstract][Full Text] [Related]
31. Current clinical regulation of PI3K/PTEN/Akt/mTOR signalling in treatment of human cancer.
Lim HJ; Crowe P; Yang JL
J Cancer Res Clin Oncol; 2015 Apr; 141(4):671-89. PubMed ID: 25146530
[TBL] [Abstract][Full Text] [Related]
32. High Sensitivity of Circulating Tumor Cells Derived from a Colorectal Cancer Patient for Dual Inhibition with AKT and mTOR Inhibitors.
Smit DJ; Cayrefourcq L; Haider MT; Hinz N; Pantel K; Alix-Panabières C; Jücker M
Cells; 2020 Sep; 9(9):. PubMed ID: 32962206
[TBL] [Abstract][Full Text] [Related]
33. Oncogenic Roles of the PI3K/AKT/mTOR Axis.
Aoki M; Fujishita T
Curr Top Microbiol Immunol; 2017; 407():153-189. PubMed ID: 28550454
[TBL] [Abstract][Full Text] [Related]
34. Targeting the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin module for acute myelogenous leukemia therapy: from bench to bedside.
Martelli AM; Tazzari PL; Evangelisti C; Chiarini F; Blalock WL; Billi AM; Manzoli L; McCubrey JA; Cocco L
Curr Med Chem; 2007; 14(19):2009-23. PubMed ID: 17691943
[TBL] [Abstract][Full Text] [Related]
35. Activation of Akt pathway by transcription-independent mechanisms of retinoic acid promotes survival and invasion in lung cancer cells.
García-Regalado A; Vargas M; García-Carrancá A; Aréchaga-Ocampo E; González-De la Rosa CH
Mol Cancer; 2013 May; 12():44. PubMed ID: 23693014
[TBL] [Abstract][Full Text] [Related]
36. The emerging role of non-coding RNAs in the regulation of PI3K/AKT pathway in the carcinogenesis process.
Ghafouri-Fard S; Abak A; Tondro Anamag F; Shoorei H; Majidpoor J; Taheri M
Biomed Pharmacother; 2021 May; 137():111279. PubMed ID: 33493969
[TBL] [Abstract][Full Text] [Related]
37. MicroRNA-99b suppresses human cervical cancer cell activity by inhibiting the PI3K/AKT/mTOR signaling pathway.
Li YJ; Wang Y; Wang YY
J Cell Physiol; 2019 Jun; 234(6):9577-9591. PubMed ID: 30480801
[TBL] [Abstract][Full Text] [Related]
38. PI3K/Akt/mTOR Signaling Pathway in Blood Malignancies-New Therapeutic Possibilities.
Wiese W; Barczuk J; Racinska O; Siwecka N; Rozpedek-Kaminska W; Slupianek A; Sierpinski R; Majsterek I
Cancers (Basel); 2023 Nov; 15(21):. PubMed ID: 37958470
[TBL] [Abstract][Full Text] [Related]
39. The emerging role of noncoding RNAs in the PI3K/AKT/mTOR signalling pathway in breast cancer.
Abu-Alghayth MH; Khan FR; Belali TM; Abalkhail A; Alshaghdali K; Nassar SA; Almoammar NE; Almasoudi HH; Hessien KBG; Aldossari MS; Binshaya AS
Pathol Res Pract; 2024 Mar; 255():155180. PubMed ID: 38330621
[TBL] [Abstract][Full Text] [Related]
40. A comprehensive immunohistochemical and molecular approach to the PI3K/AKT/mTOR (phosphoinositide 3-kinase/v-akt murine thymoma viral oncogene/mammalian target of rapamycin) pathway in bladder urothelial carcinoma.
Korkolopoulou P; Levidou G; Trigka EA; Prekete N; Karlou M; Thymara I; Sakellariou S; Fragkou P; Isaiadis D; Pavlopoulos P; Patsouris E; Saetta AA
BJU Int; 2012 Dec; 110(11 Pt C):E1237-48. PubMed ID: 23107319
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
